The nation of Zimbabwe has declined a major US healthcare agreement valued at $367m (272 million pounds) spanning five years due to the United States' insistence on sensitive data.
This move became public after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
A government representative later clarified that the US was requesting genetic material for scientific study and commercial gain while refused to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more dialogue to secure a agreement agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a court halted a similar health funding agreement after legal challenges were raised about the safety of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had administered aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral agreements to enhance openness and responsibility.
Based on reports, Sixteen nations in Africa have to date signed these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data indefinitely, with no corresponding guarantee of access to any medical innovations – like new medicines or tests – that could result from that shared data," he stated.
"In essence, our nation would provide the basic resources for medical research with no certainty that the final treatments would be available to our people if a future health crisis emerge."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its push of bilateral deals were undermining structures already set up via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This framework is intended to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how future collaboration might be arranged in a way that respects the independence and dignity of both nations."
Health Experts Response
A leading public health body said it acknowledged the government's concerns, but recommended that talks should continue considering much of the country's Aids initiatives were funded by external financing.
"Where specific concerns exist, such as those relating to information security or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," the group commented.
The situation underscores the ongoing challenges between receiving crucial international aid and protecting local interests in an increasingly interconnected world.